Presurgical Targeted Therapy with Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutic Effects

Abstract

Presurgical targeted therapy with tyrosine kinase inhibitors appears to be feasible in most patients with advanced renal cell carcinoma. However, the indications, the clinical benefit and the standard protocol still remain to be determined. Therapeutic effects in the histology were compatible to their pharmacological effects.